Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
- Associated Therapies
- -
Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Medecins Sans Frontieres, Netherlands
- Target Recruit Count
- 137
- Registration Number
- NCT03942354
- Locations
- ๐ง๐พ
Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital, Minsk, Belarus
๐บ๐ฟSh Alimov Republican Specialised Scientific-Practical Medical Centre for Phthysiology and Pulmonology Hospital, Tashkent, Uzbekistan
๐ฟ๐ฆHelen Jospeh Hospital, Johannesburg, South Africa
This Study in Healthy Men and Women Tests Whether BI 409306 Has an Effect on the ECG (Thorough QT Study)
- Conditions
- Interventions
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 47
- Registration Number
- NCT03934203
- Locations
- ๐ฉ๐ช
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism
- Conditions
- Interventions
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Signe Torekov
- Target Recruit Count
- 44
- Registration Number
- NCT03868657
- Locations
- ๐ฉ๐ฐ
University of Copenhagen, Department of Biomedical Sciences, Copenhagen, Denmark
Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose
- Conditions
- Interventions
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- Inventiva Pharma
- Target Recruit Count
- 36
- Registration Number
- NCT03866369
- Locations
- ๐ฉ๐ช
Parexel International GmbH, Berlin, Germany
A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart Function
- Conditions
- Interventions
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2019-10-31
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 44
- Registration Number
- NCT03832452
- Locations
- ๐ณ๐ฑ
QPS Netherlands B.V., Groningen, Netherlands
Clinical Study to Evaluate Effect on QT/QTc Interval After Multiple Dose of Celecoxib
- Conditions
- Interventions
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 28
- Registration Number
- NCT03822520
- Locations
- ๐ฐ๐ท
Samsung Medical Center, Seoul, Korea, Republic of
Effects of Tucatinib on Cardiac Repolarization in Healthy Participants
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT03777761
- Locations
- ๐บ๐ธ
Covance Clinical Research Unit - Dallas, Dallas, Texas, United States
A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart Function
- Conditions
- Interventions
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT03657446
- Locations
- ๐ณ๐ฑ
QPS Netherlands B.V., Groningen, Netherlands
A Study to Evaluate the PF-06700841 Effect on QTc Interval in Healthy Volunteers
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 33
- Registration Number
- NCT03656952
- Locations
- ๐ง๐ช
Pfizer Clinical Research Unit, Brussels, Belgium
Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects
- Conditions
- Interventions
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2020-03-27
- Target Recruit Count
- 72
- Registration Number
- NCT03613649
- Locations
- ๐บ๐ธ
Vince and Associates Clinical Research, Overland Park, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.